Key result
Adenosine kinase inhibition normalizes LV end-diastolic pressure by ~11 mm Hg in diabetic rats.
Why the study?
Inhibition of adenosine kinase (ADK) exerts cardiovascular protection via augmenting endogenous adenosine levels, but whether it improves microvascular dilator and left ventricle contractile function under metabolic or hemodynamic stress required investigation.
Does adenosine kinase inhibition improve microvascular dilator and left ventricle contractile function under metabolic or hemodynamic stress in rodent models?
Does adenosine kinase inhibition improve microvascular dilator and left ventricle contractile function under metabolic or hemodynamic stress in rodent models?
Adenosine kinase inhibition enhances microvascular vasodilator function and improves left ventricular perfusion and contractile function in preclinical heart failure models.
May improve diastolic function in metabolic HF models; hypothesis-generating for adenosine kinase inhibition in human HFpEF.
Objective Inhibition of adenosine kinase (ADK), via augmenting endogenous adenosine levels exerts cardiovascular protection. We tested the hypothesis that ADK inhibition improves microvascular dilator and left ventricle (LV) contractile function under metabolic or hemodynamic stress. Methods and Results In Obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid rats, treatment with the selective ADK inhibitor, ABT‐702 (1.5 mg/kg, intraperitoneal injections for 8‐week) restored acetylcholine‐, sodium nitroprusside‐, and adenosine‐induced dilations in isolated coronary arterioles, an effect that was accompanied by normalized end‐diastolic pressure (in mm Hg, Lean: 3.4 ± 0.6, Obese: 17.6 ± 4.2, Obese + ABT: 6.6 ± 1.4) and LV relaxation constant, Tau (in ms, Lean: 6.9 ± 1.5, Obese: 13.9 ± 1.7, Obese + ABT: 6.0 ± 1.1). Mice with vascular endothelium selective ADK deletion (ADK VEC KO) exhibited an enhanced dilation to acetylcholine in isolated gracilis muscle (lgEC 50 WT: −8.2 ± 0.1, ADK VEC KO: −8.8 ± 0.1, P < .05) and mesenteric arterioles (lgEC 50 WT: −7.4 ± 0.2, ADK VEC KO: −8.1 ± 1.2, P < .05) when compared to wild‐type (WT) mice, whereas relaxation of the femoral artery and aorta (lgEC 50 WT: −7.03 ± 0.6, ADK VEC KO: −7.05 ± 0.8) was similar in the two groups. Wild‐type mice progressively developed LV systolic and diastolic dysfunction when they underwent transverse aortic constriction surgery, whereas ADK VEC ‐KO mice displayed a lesser degree in decline of LV function. Conclusions Our results indicate that ADK inhibition selectively enhances microvascular vasodilator function, whereby it improves LV perfusion and LV contractile function under metabolic and hemodynamic stress.
No takes yet. Share an insight, caveat, or question.
Davila et al. (2020) studied Obese diabetic Zucker fatty/spontaneously hypertensive heart failure F1 hybrid rats and ADK VEC KO mice with LV dysfunction (n=20). Adenosine kinase (ADK) inhibition (ABT-702 or genetic deletion) vs. Vehicle or Wild-type was evaluated on Left ventricular end-diastolic pressure in obese ZSF1 rats. Adenosine kinase inhibition with ABT-702 normalized end-diastolic pressure (6.6 vs 17.6 mm Hg) and LV relaxation constant in obese diabetic rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: